Sotrastaurin - AEB 071 | NVP-AEB 071

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 1635

CAS [425637-18-9]

MF C25H22N6O2
MW 438.48

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

Sotrastaurin

Description

Potent and specific inhibitor of protein kinase C (PKC) with Ki at subnanomolar to low nanomolar range for a variety of PKC isotypes while selective for >200 other kinases; an immunosuppressant that blocks early T-lymphocyte (T-cell) activation via protein kinase C inhibition.

G Weckbecker et al. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. Transplant Int. 2010, 23(5), 543-552.

K Budde et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am. J. Transplant. 2010, 10(3), 571-581.

M McCall et al.?Sotrastaurin. Drugs Fut. 2009, 34(8), 618-623.

JP Evenou et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J. Pharm. Exp. Ther. 2009, 330(3), 792-801.

H Skvara et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 2008, 118(9), 3151–3159.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Immunology Pain & Inflammation Immunomodulator NF-κB PI3K-Akt-mTOR EC 2.7.11.13 PKC

PKC inhibitor

Chemical name

3-(1H-indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4-yl)-1H-pyrrole-2,5-dione

Parent CAS No.

[425637-18-9]

產(chǎn)品資料